The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
The company is already marketing the 4 mg and 10 mg strengths
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Subscribe To Our Newsletter & Stay Updated
